이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

성인 만성 염증성 탈수초성 다발신경병증(CIDP)에 대한 니포칼리맙의 효능 및 안전성 연구

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

만성 염증성 탈수초성 다발신경병증(CIDP)이 있는 성인에게 투여된 니포칼리맙의 효능 및 안전성을 평가하기 위한 2/3상, 다단계, 다기관, 무작위배정, 이중맹검, 위약 대조 병렬 그룹 철회 연구

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

연구 개요

연구 유형

중재적

등록 (추정된)

201

단계

  • 2 단계
  • 3단계

확장된 액세스

일시적으로 사용할 수 없음 임상시험 외. 확장 액세스 기록을 참조하세요.

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Athens, 그리스, 12462
        • 모병
        • Attikon General Hospital of Athens
      • Athens, 그리스, 11527
        • 완전한
        • Papageorgiou General Hospital Of Thessaloniki
      • Pátrai, 그리스, 26504
        • 완전한
        • Patras University Hospital
      • Thessaloniki, 그리스, 54636
        • 모병
        • Ahepa Hospital Aristotle University of Thessaloniki
      • Kaohsiung City, 대만, 88301
        • 완전한
        • Kaohsiung Chang Gung Memorial Hospital
      • Taipei, 대만, 100
        • 모집하지 않고 적극적으로
        • National Taiwan University Hospital
      • Taipei, 대만, 111
        • 모집하지 않고 적극적으로
        • Shin Kong Wu Ho Su Memorial Hospital
      • Seoul, 대한민국, 05030
        • 완전한
        • Konkuk University Medical Center
      • Seoul, 대한민국, 02447
        • 완전한
        • Kyunghee University Medical Center
      • Seoul, 대한민국, 135-710
        • 완전한
        • Samsung Medical Center
      • Berlin, 독일, 13347
        • 모집하지 않고 적극적으로
        • Judisches Krankenhaus Berlin
      • Bochum, 독일, 44791
        • 완전한
        • St. Josef-Hospital, Ruhr-Universität Bochum
      • Halle, 독일, 6120
        • 모집하지 않고 적극적으로
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Hanover, 독일, 30625
        • 모집하지 않고 적극적으로
        • Medizinische Hochschule Hannover
      • Leipzig, 독일, 4103
        • 완전한
        • Universitaetsklinikum Leipzig
      • Potsdam, 독일, 14471
        • 완전한
        • St Josefs Krankenhaus Potsdam Sanssouci
      • Monterrey, 멕시코, 64710
        • 완전한
        • i Can Oncology Center
      • Tlalnepantla, 멕시코, 54055
        • 모병
        • Clinical Research Institute S.C.
    • Colorado
      • Centennial, Colorado, 미국, 80112
        • 모집하지 않고 적극적으로
        • IMMUNOe Health and Research Centers
    • Florida
      • Coral Springs, Florida, 미국, 33067
        • 완전한
        • Healthcare Innovations Institute Inc
      • Maitland, Florida, 미국, 32751
        • 완전한
        • Neurology Associates PA
      • Miami, Florida, 미국, 33136
        • 모집하지 않고 적극적으로
        • ALS Center at the University of Miami
    • Georgia
      • Augusta, Georgia, 미국, 30912
        • 완전한
        • Augusta University
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • 완전한
        • University of Kansas Medical Center
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • 완전한
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, 미국, 02111
        • 완전한
        • Boston Clinical Trials
    • Michigan
      • Royal Oak, Michigan, 미국, 48073
        • 완전한
        • Beaumont Hospital Royal Oak
    • Missouri
      • Kansas City, Missouri, 미국, 64128
        • 완전한
        • Kansas City Veterans Affairs Medical Center
    • New York
      • New York, New York, 미국, 10032
        • 완전한
        • The Neurological Institute of New York
      • Patchogue, New York, 미국, 11772
        • 완전한
        • South Shore Neurologic Associates - Patchogue
    • North Carolina
      • Charlotte, North Carolina, 미국, 28204
        • 완전한
        • The Neurological Institute, PA
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 모집하지 않고 적극적으로
        • Cleveland Clinic Main Campus
    • Texas
      • Austin, Texas, 미국, 78756
        • 완전한
        • Austin Neuromuscular Center
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53215
        • 모집하지 않고 적극적으로
        • Advocate Health - Aurora St. Luke's Medical Center
      • Alicante, 스페인, 03010
        • 모집하지 않고 적극적으로
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, 스페인, 8035
        • 완전한
        • Hosp Univ Vall D Hebron
      • Bilbao, 스페인, 48013
        • 모집하지 않고 적극적으로
        • Hosp. Univ. de Basurto
      • Donostia / San Sebastian, 스페인, 20014
        • 완전한
        • Hosp. Univ. Donostia
      • Madrid, 스페인, 28040
        • 완전한
        • Hosp. Clinico San Carlos
      • Seville, 스페인, 41009
        • 모집하지 않고 적극적으로
        • Hosp. Virgen Macarena
      • Buenos Aires, 아르헨티나, C1199ABB
        • 모집하지 않고 적극적으로
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, 아르헨티나, C1428AQK
        • 모병
        • Instituto Fleni
      • Buenos Aires, 아르헨티나, C1428
        • 완전한
        • Hospital Gral Agudos Ignacio Pirovano
      • Rosario, 아르헨티나, 2900
        • 모병
        • INECO Neurociencias Orono
      • Birmingham, 영국, B15 2TH
        • 완전한
        • University Hospitals Birmingham NHS Foundation Trust
      • Devon, 영국, EX2 5DW
        • 완전한
        • Royal Devon & Exeter Hospital
      • Glasgow, 영국, G514TF
        • 모집하지 않고 적극적으로
        • NHS Greater Glasgow and Clyde
      • London, 영국, NW3 2QG
        • 완전한
        • Royal Free Hospital
      • Sheffield, 영국, S10 2 JF
        • 모집하지 않고 적극적으로
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Catania, 이탈리아, 95123
        • 완전한
        • Azienda Ospedaliero-Universitaria Policlinico di Catania
      • Genova, 이탈리아, 16132
        • 완전한
        • Azienda Ospedaliera Universitaria San Martino di Genova
      • Milan, 이탈리아, 20144
        • 완전한
        • Casa di Cura del Policlinico
      • Milan, 이탈리아, 20133
        • 완전한
        • Istituto Neurologico Carlo Besta
      • Naples, 이탈리아, 80131
        • 모집하지 않고 적극적으로
        • Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
      • Orbassano, 이탈리아, 10043
        • 완전한
        • Aou San Luigi Gonzaga
      • Pavia, 이탈리아, 27100
        • 완전한
        • Fondazione Istituto Neurologico Casimiro Mondino
      • Roma, 이탈리아, 00168
        • 완전한
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Rozzano, 이탈리아, 20086
        • 완전한
        • IRCCS Istituto Clinico Humanitas
      • Asahikawa, 일본, 070-0901
        • 모집하지 않고 적극적으로
        • National Hospital Organization Asahikawa Medical Center
      • Bunkyō City, 일본, 113 8519
        • 모집하지 않고 적극적으로
        • Institute of Science Tokyo Hospital
      • Chiba, 일본, 260-8677
        • 완전한
        • Chiba University Hospital
      • Hamamatsu, 일본, 430-8558
        • 모집하지 않고 적극적으로
        • Seirei Hamamatsu General Hospital
      • Isehara, 일본, 259-1193
        • 모집하지 않고 적극적으로
        • Tokai University Hospital
      • Kobe, 일본, 650 0047
        • 완전한
        • Kobe City Medical Center General Hospital
      • Kodaira-shi, 일본, 187-8551
        • 모집하지 않고 적극적으로
        • National Center of Neurology and Psychiatry
      • Koshigaya, 일본, 343-8555
        • 모집하지 않고 적극적으로
        • Saitama Medical Center
      • Kumamoto, 일본, 860-8556
        • 완전한
        • Kumamoto University Hospital
      • Nagoya, 일본, 466-8560
        • 모집하지 않고 적극적으로
        • Nagoya University Hospital
      • Nagoya, 일본, 455-8530
        • 모집하지 않고 적극적으로
        • Chubu Rosai Hospital
      • Osaka Sayama Shi, 일본, 589 8511
        • 완전한
        • Kindai University Hospital
      • Sendai, 일본, 983-8520
        • 모집하지 않고 적극적으로
        • National Hospital Organization Sendai Medical Center
      • Shimotsuga Gun, 일본, 321 0293
        • 완전한
        • Dokkyo Medical University Hospital
      • Shinjuku-ku, 일본, 162-8666
        • 완전한
        • Tokyo Women's Medical University Hospital
      • Tenri, 일본, 632-0015
        • 완전한
        • Tenri Hospital
      • Toon-shi, 일본, 791-0295
        • 완전한
        • Ehime University Hospital
      • Toyama, 일본, 930-0194
        • 완전한
        • Toyama University Hospital
      • Ube, 일본, 755-8505
        • 완전한
        • Yamaguchi University Hospital
      • Beijing, 중국, 100191
        • 완전한
        • Peking University Third Hospital
      • Beijing, 중국, 100034
        • 완전한
        • Peking University First Hospital
      • Beijing, 중국, 100053
        • 모집하지 않고 적극적으로
        • Xuanwu Hospital ,Capital Medical University
      • Beijing, 중국, 100070
        • 모집하지 않고 적극적으로
        • Beijing Tiantan Hospital, Capital Medical University
      • Changchun, 중국, 130021
        • 모집하지 않고 적극적으로
        • The First Hospital of Jilin University
      • Changsha, 중국, 410008
        • 완전한
        • Xiangya Hospital Central South University
      • Changsha, 중국, 410008
        • 모집하지 않고 적극적으로
        • The Third Xiangya Hospital of Central Sourth University
      • Chengdu, 중국, 610072
        • 완전한
        • Sichuan Provincial Peoples Hospital
      • Chifeng, 중국, 024000
        • 완전한
        • Chifeng Municipal Hospital
      • Fuzhou, 중국, 350001
        • 모집하지 않고 적극적으로
        • Fujian Medical University Union Hospital
      • Guangzhou, 중국, 510080
        • 모집하지 않고 적극적으로
        • The First Affiliated Hospital Sun Yat sen University
      • Jinan, 중국, 250012
        • 모집하지 않고 적극적으로
        • Qilu Hospital of Shandong University
      • Jinan, 중국, 250014
        • 완전한
        • Qianfoshan hospital of Shandong Province
      • Nanchang, 중국, 330006
        • 모집하지 않고 적극적으로
        • The First Affiliated Hospital of NanChang University
      • Shanghai, 중국, 200336
        • 완전한
        • Tong Ren Hospital Shanghai Jiao Tong University school of medicine
      • Shanghai, 중국, 200040
        • 모집하지 않고 적극적으로
        • Huashan Hospital Fudan University
      • Wuhan, 중국, 430023
        • 완전한
        • Renmin Hospital of Wuhan University
      • Xi'an, 중국, 710032
        • 완전한
        • Tangdu hospital the Fourth Military Medical
      • Xi'an, 중국, 710075
        • 모집하지 않고 적극적으로
        • Xi 'an GaoXin Hospital
      • Hradec Králové, 체코, 500 05
        • 모집하지 않고 적극적으로
        • Fakultni nemocnice Hradec Kralove
      • Ostrava, 체코, 708 52
        • 완전한
        • Fakultni Nemocnice Ostrava
      • Pardubice, 체코, 53203
        • 완전한
        • Pardubicka krajska nemocnice a s
      • Ottawa, 캐나다, K1N 6N5
        • 모병
        • The Ottawa Hospital Ottawa NeuroMuscular Centre
      • Floridablanca, 콜롬비아, 681004
        • 완전한
        • Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
      • Medellín, 콜롬비아, 50021
        • 모집하지 않고 적극적으로
        • Instituto Neurológico de Colombia
      • Almada, 포르투갈, 2805-267
        • 모집하지 않고 적극적으로
        • Hospital Garcia de Orta
      • Braga, 포르투갈, 4710-243
        • 완전한
        • Hospital de Braga
      • Porto, 포르투갈, 4200 319
        • 모집하지 않고 적극적으로
        • Centro Hospitalar de Sao Joao Epe
      • Chorzów, 폴란드, 41 500
        • 완전한
        • Centrum Medyczne
      • Krakow, 폴란드, 30 539
        • 완전한
        • Specjalistyczne Gabinety Lekarskie
      • Lublin, 폴란드, 20 093
        • 완전한
        • Prywatny Gabinet Lekarski
      • Poznan, 폴란드, 61 731
        • 모집하지 않고 적극적으로
        • Clinical Research Center sp z o o MEDIC R s k
      • Bordeaux, 프랑스, 33000
        • 완전한
        • CHU Bordeaux
      • Bron, 프랑스, 69699
        • 완전한
        • Hospices Civils de Lyon HCL
      • Le Kremlin-Bicêtre, 프랑스, 94270
        • 모집하지 않고 적극적으로
        • Hopital de Bicetre
      • Marseille, 프랑스, 13385
        • 모집하지 않고 적극적으로
        • Hopital de la Timone
      • Nice, 프랑스, 06000
        • 모집하지 않고 적극적으로
        • Hopital PASTEUR
      • Nîmes, 프랑스, 30029
        • 모집하지 않고 적극적으로
        • CHU Nimes Hopital Caremeau
      • Paris, 프랑스, 75013
        • 완전한
        • Hopital de la Pitie Salpetriere
      • Paris, 프랑스, 75019
        • 완전한
        • Fondation Adolphe de Rothschild Hospital
      • Strasbourg, 프랑스, 67200
        • 모집하지 않고 적극적으로
        • CHRU Strasbourg
      • Melbourne, 호주, 3004
        • 완전한
        • The Alfred Hospital
      • Parkwood, 호주, 4215
        • 완전한
        • Gold Coast University Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
  • Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
  • Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
  • Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
  • Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
  • Other protocol-defined inclusion criteria will apply

Exclusion Criteria:

  • Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
  • Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
  • Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
  • Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
  • Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
  • Other protocol-defined exclusion criteria will apply

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Nipocalimab

Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Nipocalimab will be administered intravenously.

다른 이름들:
  • JNJ-80202135
  • M281
위약 비교기: Placebo

Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Placebo will be administered intravenously.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Stage B: Time to First Occurrence of a Relapse Event
기간: Up to 52 weeks

Stage B time to first occurrence of a relapse event will be reported.

Up to 52 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
기간: 12 weeks

Time to initial confirmed ECI will be reported.

12 weeks
Stage A: Percentage of Responders as Determined by ECI
기간: 12 weeks

Stage A percentage of responders as determined by ECI will be reported.

12 weeks
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
기간: Baseline to 12 weeks

Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability.

Baseline to 12 weeks
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
기간: Baseline to 12 weeks

Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
기간: Baseline to 12 weeks

Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
기간: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
기간: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
기간: Up to 52 weeks

Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
기간: Up to 52 weeks

Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
기간: Up to 52 weeks

Change from Stage B baseline over time in adjusted INCAT disability score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
기간: Up to 52 weeks

Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in I-RODS Centile Score
기간: Up to 52 weeks

Change from Stage B baseline over time in I-RODS centile score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
기간: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
기간: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
기간: Up to 52 weeks

Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported.

Up to 52 weeks
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Serious Adverse Events (SAEs)
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in ECG values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Vital Signs Values Over Time
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in vital signs values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Clinical Laboratory Values Over Time
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in clinical laboratory values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant ECG Abnormalities
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant ECG abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Vital Signs Abnormalities
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant vital signs abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant clinical laboratory abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with ADA to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Titers of ADA to Nipocalimab
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Titers of ADA to nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
기간: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with NAb to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
기간: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Change from baseline in total serum IgG concentrations levels over time will be reported.

Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 9월 23일

기본 완료 (추정된)

2026년 12월 15일

연구 완료 (추정된)

2028년 7월 11일

연구 등록 날짜

최초 제출

2022년 4월 7일

QC 기준을 충족하는 최초 제출

2022년 4월 7일

처음 게시됨 (실제)

2022년 4월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CR109195
  • 80202135CDP3001 (기타 식별자: Janssen Research & Development, LLC)
  • 2021-003234-37 (EudraCT 번호)
  • 2023-508425-28-00 (레지스트리 식별자: EUCT number)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다